Bausch + Lomb Launches Innovative Bausch + Lomb INFUSE™ Silicone Hydrogel (SiHy) Daily Disposable Contact Lenses
Bausch + Lomb has launched the INFUSE™ silicone hydrogel daily disposable contact lens, designed to combat contact lens dryness affecting about half of U.S. lens wearers. This lens utilizes ProBalance Technology™ to maintain ocular surface homeostasis and retain 96% moisture for 16 hours. The advanced design aims to provide comfort without sacrificing vision correction. Bausch Health Companies Inc. (NYSE/TSX: BHC) emphasizes its commitment to innovative eye care solutions, reflecting the need for advanced materials in contact lens technology.
- Launch of INFUSE™ contact lenses addresses dryness for 50% of U.S. lens wearers.
- ProBalance Technology™ enhances moisture retention and comfort.
- The lens maintains 96% moisture for 16 hours, supporting user comfort.
- None.
Next Generation Material Infused with Proprietary ProBalance Technology™ to Help Maintain Ocular Surface Homeostasis and Help Reduce Contact Lens Dryness, Which Affects More Than Half of Lens Wearers in the United States
LAVAL, Quebec, Aug. 17, 2020 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the launch of Bausch + Lomb INFUSE™ silicone hydrogel (SiHy) daily disposable contact lens, the only SiHy daily disposable with a next generation material infused with ProBalance Technology™ to help ocular surface homeostasis and help reduce symptoms of contact lens dryness, which is experienced by approximately half1 of the 45 million lens wearers in the United States.2,3
"Our Bausch + Lomb INFUSE SiHy daily disposable lens combines innovative design and advanced technology to provide support for dryness as a barrier to contact lens wear," said Joe Gordon, U.S. president, Bausch + Lomb. "Bausch + Lomb INFUSE is designed with an advanced silicone hydrogel daily disposable lens to help reduce symptoms of contact lens dryness and is a testament to our ongoing commitment to apply the latest science to meet the needs of patients and eye care providers."
Bausch + Lomb INFUSE contact lenses feature a next-generation SiHy daily disposable lens material (kalifilcon A) and ProBalance Technology™ that work together to help maintain ocular surface homeostasis to help reduce contact lens dryness and discomfort. The ProBalance Technology™ formula is infused into the lens material during the manufacturing process. These proprietary ingredients are released during lens wear. Bausch + Lomb INFUSE combines exceptional breathability for healthy lens wear with the highest moisture content and lowest modulus among SiHy daily disposables*, and it maintains
"Many of my patients believe they have to sacrifice comfort for vision correction due to contact lens dryness. I'm excited to be able to offer them a new lens design that goes beyond material characteristics to look at how the lens material and solution technology can work together," said Arthur B. Epstein, O.D., Director of Clinical Research and the Dry Eye and Ocular Surface Disease Center, Phoenix Eye Care. "By understanding the ocular environment in which a contact lens resides, Bausch + Lomb was able to address patients' needs by seeking a different approach and design that helps maintain ocular surface homeostasis to help reduce symptoms of contact lens dryness."
For more information on Bausch + Lomb INFUSE contact lenses, visit www.BauschInfuse.com and www.BauschInfuse.com/ECP.
About Bausch + Lomb
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
*Versus leading silicone hydrogel daily disposables, DAILIES TOTAL1 and ACUVUE OASYS 1-DAY, based on dollar share of segment.
INFUSE is a trademark of Bausch & Lomb Incorporated or its affiliates.
© 2020 Bausch & Lomb Incorporated or its affiliates.
INF.0166.USA.20
- National Institutes of Health. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628947/
- American Optometric Association. https://www.aoa.org/patients-and-public/caring-for-your-vision/contact-lenses/facts-and-stats
- Centers for Disease Control and Prevention. https://www.cdc.gov/contactlenses/fast-facts.html#:~:text=An%20estimated%
2045% 20million%20people,is%2031% 20years%20old%202
Investor Contact: | Media Contact: |
Arthur Shannon | Lainie Keller |
(514) 856-3855 | (908) 927-1198 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-launches-innovative-bausch--lomb-infuse-silicone-hydrogel-sihy-daily-disposable-contact-lenses-301112825.html
SOURCE Bausch Health Companies Inc.
FAQ
What is the new product launched by Bausch Health Companies Inc.?
How does the INFUSE™ lens help with contact lens dryness?
What percentage of contact lens wearers in the U.S. experience dryness?
What is the moisture retention capability of the INFUSE™ lens?
What is the stock symbol for Bausch Health Companies Inc.?
